Medtronic has entered a new outcomes-based agreement with US healthcare firm Aetna to investigate health outcomes in diabetes patients switching to pump therapy using its insulin pump that employs SmartGuard Technology and the new MiniMed 670G system.

The solution is designed to self-adjust to maintain patients blood sugar levels according to their personal requirements.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study will include type 1 and type 2 diabetes patients who are currently on several daily insulin injections for diabetes management.

In addition to the MiniMed 670G system, the agreement will provide Aetna members with access to Medtronic's other advanced diabetes technologies and support services.

"Our goal is to continue to lead by driving innovation that demonstrably improves patient outcomes, elevates patient experience, and lowers the total cost of care."

Medtronic Diabetes Group president Hooman Hakami said: "Our goal is to continue to lead by driving innovation that demonstrably improves patient outcomes, elevates patient experience, and lowers the total cost of care.

“The growing body of clinical evidence demonstrating the benefits of our proprietary SmartGuard Technology is compelling and we are pleased to work with Aetna to drive awareness and align incentives around the technologies that make the biggest difference for patients and for the health system."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The deal also includes Medtronic's reimbursement depending on clinical improvement thresholds for Aetna members switching to the insulin pump.

Medtronic Diabetes Group Americas group vice-president said: "This agreement is an important first step as we look to broadening our partnership to facilitate patient access to the most advanced diabetes management solutions across the care continuum that not only ensure outcomes, but lower the overall cost of care for this chronic and burdensome disease."

Image: MiniMed 670G system. Photo: courtesy of Medtronic plc.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact